SHANGHAI, Oct. 21, 2014 /PRNewswire/ -- WuXi PharmaTech
(Cayman) Inc. (NYSE: WX), a leading open-access R&D capability
and technology platform company serving the pharmaceutical,
biotechnology and medical device industries, with operations in
China and the United States, today announced that it
will release financial results for the third quarter of 2014 after
the New York Stock Exchange closes on Wednesday, November 12, 2014 (which will be
Thursday morning, November 13, 2014
Shanghai time). The earnings release will be available on the
investor relations section of the Company's website at
http://www.wuxiapptec.com/.
Following the earnings announcement, WuXi PharmaTech senior
management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 9:00 pm (Beijing/Shanghai/Hong
Kong) on Thursday, November 13,
2014, to discuss the third-quarter 2014 financial results
and recent business activities. The conference call may be accessed
by calling:
Mainland
China
|
4001 200 539
|
Hong Kong
|
800 905 927
|
Singapore
|
800 616 3222
|
United
Kingdom
|
0800 015 9725
|
United
States
|
1855 298 3404
|
United States—New
York (toll)
|
+1 631 5142 526
|
Other countries
(toll)
|
+65 6823 2299
|
Conference
ID
|
7520886
|
A telephone replay will be available two hours after the call's
completion at:
Mainland
China
|
4001 842 240
|
Hong Kong
|
800 966 697
|
Singapore
|
800 616 2127
|
United
Kingdom
|
0800 169 7301
|
United
States
|
1866 846 0868
|
Conference
ID
|
7520886
|
A live webcast of the conference call and replay will be
available in the investor relations section of WuXi PharmaTech's
website at http://www.wuxiapptec.com/.
About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and
technology platform company serving the pharmaceutical,
biotechnology and medical device industries, with operations in
China and the United States. As a research-driven and
customer-focused company, WuXi PharmaTech provides pharmaceutical,
biotechnology and medical device companies with a broad and
integrated portfolio of laboratory and manufacturing services
throughout the drug and medical device R&D process. WuXi
PharmaTech's services are designed to help its global partners in
shortening the cycle and lowering the cost of drug and medical
device R&D. The operating subsidiaries of WuXi PharmaTech are
known as WuXi AppTec.
For more information, please contact:
Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com
Web: http://www.wuxiapptec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wuxi-pharmatech-schedules-third-quarter-2014-earnings-release-665682557.html
SOURCE WuXi PharmaTech (Cayman) Inc.